ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

In this episode, listen to Ana Oaknin, MD, PhD and Alexandra Leary, MD, PhD, share their clinical insights and takeaways on key updates and new data presented for ovarian, endometrial, and cervical cancer at the ESMO 2024 annual congress including:Phase III PRIMA/ENGOT-OV26/GOG-3012 Final OS Results: Niraparib as First-Line Maintenance in Advanced Ovarian CancerATHENA COMBO/GOG-3020/ENGOT-ov45: Rucaparib With or Without Nivolumab Maintenance in Newly Diagnosed Ovarian CancerPhase II PICCOLO Trial of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive Ovarian Cancer With High-FRα ExpressionPhase III KEYNOTE-B21/GOG-3053 Study of Adjuvant Chemotherapy With or Without Radiotherapy With or Without Pembrolizumab in Patients With Newly Diagnosed Endometrial Cancer or Carcinosarcoma After Curative Surgery With no Residual DiseasePhase III KEYNOTE-A18 Overall Survival Results: Pembrolizumab Plus Concurrent Chemoradiation in High-Risk Locally Advanced Cervical Cancer Program faculty:Ana Oaknin, MD, PhDHead of Gynaecologic Cancer ProgrammeDepartment of Medical OncologyVall d’ Hebron University HospitalVall d’Hebron Institute of Oncology Barcelona, SpainAlexandra Leary, MD, PhDCo-Director, Department of Medical OncologyMedical Oncologist, GynecologyTeam Leader, Gynecologic Translational Research Lab, Institut Gustave RoussyParis, FranceResources:To download the slides associated with this podcast discussion, please visit the program page.

There are no comments yet.

Please log in to write the first comment.